# A Phase II Dose Response Study in Japan in Chronic Hepatitis B

> **NCT01022801** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT01022801
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2010-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01022801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01022801, "A Phase II Dose Response Study in Japan in Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01022801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*